Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2563)	8/19/2009 11:31:03 AM
From: Jibacoa	Respond to of 3722

CERS opened with a good UG and is still up 74.3% on volume already above the 10,420,000, about 29x its ADV.<g> The stock is still trading above the $3, the H at the time of its previous spike on Jul27. bigcharts.marketwatch.com It announced today that Swissmedic has approved the use of its INTERCEPT Blood System. The approval extends permitted storage time for platelets to seven days with INTERCEPT treatment, compared to five days without treatment.France and Germany had already approved the INTERCEPT Blood System and CERS had previously received CE mark approval for its INTERCEPT platelet and plasma systems, which allows CERS to sell the systems in the European Union. CERS has negligible LTD and in spite of its large burn rate, it seems that it still has room to run, albeit it may be prudent to wait and see if it will close some of today's UG.<g> bigcharts.marketwatch.com Bernard